Erwin Surmann

1.2k total citations
19 papers, 876 citations indexed

About

Erwin Surmann is a scholar working on Neurology, Epidemiology and Psychiatry and Mental health. According to data from OpenAlex, Erwin Surmann has authored 19 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Neurology, 5 papers in Epidemiology and 3 papers in Psychiatry and Mental health. Recurrent topics in Erwin Surmann's work include Parkinson's Disease Mechanisms and Treatments (18 papers), Neurological disorders and treatments (11 papers) and Botulinum Toxin and Related Neurological Disorders (10 papers). Erwin Surmann is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (18 papers), Neurological disorders and treatments (11 papers) and Botulinum Toxin and Related Neurological Disorders (10 papers). Erwin Surmann collaborates with scholars based in Germany, United States and Belgium. Erwin Surmann's co-authors include Babak Boroojerdi, К. Ray Chaudhuri, Claudia Trenkwalder, L. Ghys, John Whitesides, Lars Bauer, Werner Poewe, Jan Kassubek, Mahnaz Asgharnejad and Bryan Kies and has published in prestigious journals such as Neurology, Movement Disorders and Clinical Therapeutics.

In The Last Decade

Erwin Surmann

19 papers receiving 858 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erwin Surmann Germany	15	818	244	200	108	87	19	876
Allison Dicke United States	6	491 0.6×	117 0.5×	137 0.7×	145 1.3×	86 1.0×	6	612
Alice J. Manson United Kingdom	10	774 0.9×	43 0.2×	135 0.7×	287 2.7×	65 0.7×	12	860
Dee E. Silver United States	14	491 0.6×	62 0.3×	82 0.4×	165 1.5×	55 0.6×	23	604
Mubasher A. Qamar United Kingdom	11	339 0.4×	71 0.3×	69 0.3×	87 0.8×	32 0.4×	24	409
Pedro Chaná Chile	11	448 0.5×	69 0.3×	103 0.5×	92 0.9×	123 1.4×	21	626
Shirley Lasch United States	8	557 0.7×	144 0.6×	219 1.1×	99 0.9×	65 0.7×	8	619
Philip A. Hanna United States	10	370 0.5×	43 0.2×	108 0.5×	150 1.4×	85 1.0×	13	593
Lucy M. Blasucci United States	9	541 0.7×	56 0.2×	235 1.2×	128 1.2×	94 1.1×	9	767
Raquel N. Taddei United Kingdom	10	224 0.3×	65 0.3×	112 0.6×	77 0.7×	49 0.6×	15	445
Erika Driver‐Dunckley United States	11	652 0.8×	66 0.3×	239 1.2×	140 1.3×	201 2.3×	22	798

Countries citing papers authored by Erwin Surmann

Since Specialization

Citations

This map shows the geographic impact of Erwin Surmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erwin Surmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erwin Surmann more than expected).

Fields of papers citing papers by Erwin Surmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erwin Surmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erwin Surmann. The network helps show where Erwin Surmann may publish in the future.

Co-authorship network of co-authors of Erwin Surmann

This figure shows the co-authorship network connecting the top 25 collaborators of Erwin Surmann. A scholar is included among the top collaborators of Erwin Surmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erwin Surmann. Erwin Surmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Liu, Yun, Brian Tomlinson, Mahnaz Asgharnejad, et al.. (2018). Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese Subjects. Clinical Therapeutics. 40(7). 1108–1121.e8. 3 indexed citations

Zhang, Zhenxin, Chun‐Feng Liu, Enxiang Tao, et al.. (2017). Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study. Parkinsonism & Related Disorders. 44. 6–12. 18 indexed citations

Hauser, Robert A., Jarosław Sławek, Paolo Barone, et al.. (2016). Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease. BMC Neurology. 16(1). 90–90. 46 indexed citations

Zhang, Zhenxin, Huifang Shang, Xingyue Hu, et al.. (2016). Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study. Parkinsonism & Related Disorders. 28. 49–55. 23 indexed citations

Rascol, Olivier, Theresa Zesiewicz, К. Ray Chaudhuri, et al.. (2015). A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain. The Journal of Clinical Pharmacology. 56(7). 852–861. 80 indexed citations

Nicholas, Anthony P., Rupam Borgohain, Pedro Chaná, et al.. (2014). A Randomized Study of Rotigotine Dose Response on ‘Off’ Time in Advanced Parkinson's Disease. Journal of Parkinson s Disease. 4(3). 361–373. 36 indexed citations

Swick, Todd J., Joseph H. Friedman, К. Ray Chaudhuri, et al.. (2014). Associations between Severity of Motor Function and Nonmotor Symptoms in Parkinson's Disease: A Post Hoc Analysis of the RECOVER Study. European Neurology. 71(3-4). 140–147. 14 indexed citations

Kassubek, Jan, К. Ray Chaudhuri, Theresa Zesiewicz, et al.. (2014). Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hocanalysis of the RECOVER study. BMC Neurology. 14(1). 42–42. 48 indexed citations

Giladi, Nir, L. Ghys, Erwin Surmann, Babak Boroojerdi, & Joseph Jankovic. (2014). Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism & Related Disorders. 20(12). 1345–1351. 21 indexed citations

10.

Giladi, Nir, Babak Boroojerdi, & Erwin Surmann. (2013). The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson’s disease. Journal of Neural Transmission. 120(9). 1321–1329. 28 indexed citations

11.

Chaudhuri, К. Ray, Pablo Martínez‐Martín, Angelo Antonini, et al.. (2013). Rotigotine and specific non-motor symptoms of Parkinson's disease: Post hoc analysis of RECOVER. Parkinsonism & Related Disorders. 19(7). 660–665. 108 indexed citations

12.

Elmer, Lawrence, Erwin Surmann, Babak Boroojerdi, & Joseph Jankovic. (2012). Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson’s disease: A prospective, open-label extension study. Parkinsonism & Related Disorders. 18(5). 488–493. 36 indexed citations

13.

LeWitt, Peter A., Babak Boroojerdi, Erwin Surmann, & Werner Poewe. (2012). Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. Journal of Neural Transmission. 120(7). 1069–1081. 36 indexed citations

14.

Trenkwalder, Claudia, Bryan Kies, Péter Diószeghy, et al.. (2012). Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson’s disease: Results from a 1-year, open-label extension of the RECOVER study. Research Portal (King's College London). 2(2). 79–85. 14 indexed citations

15.

Hauser, Robert A., Paul A. Nausieda, Erwin Surmann, K. Moran, & Paolo Barone. (2012). Rotigotine Transdermal System Improves Neuropsychiatric Features (Apathy, Anhedonia, Anxiety, and Depression) and Fatigue in Patients with Parkinson's Disease: A Post-Hoc Analysis of Five Double-Blind Placebo-Controlled Studies (P06.088). Neurology. 78(Meeting Abstracts 1). P06.088–P06.088. 1 indexed citations

16.

Cawello, Willi, Erwin Surmann, & J. Waitzinger. (2012). Lacosamide Has No Effect on the Enzymatic Activity of CYP3A4 (P01.076). Neurology. 78(Meeting Abstracts 1). P01.076–P01.076. 3 indexed citations

17.

Ghys, L., Erwin Surmann, John Whitesides, & Babak Boroojerdi. (2011). Effect of rotigotine on sleep and quality of life in Parkinson's disease patients:post hocanalysis of RECOVER patients who were symptomatic at baseline. Expert Opinion on Pharmacotherapy. 12(13). 1985–1998. 33 indexed citations

18.

Trenkwalder, Claudia, Bryan Kies, Monika Rudzińska, et al.. (2010). Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER). Movement Disorders. 26(1). 90–99. 326 indexed citations

19.

Trenkwalder, C., К. Ray Chaudhuri, Tim Anderson, et al.. (2009). P2.170 Effect of rotigotine on control of early morning motor function and sleep quality in subjects with idiopathic Parkinson's disease. Parkinsonism & Related Disorders. 15. S136–S136. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact